150 related articles for article (PubMed ID: 12801794)
1. Tumor markers: discovery to practice.
Zhang WW
Drug Discov Today; 2003 May; 8(10):441-3. PubMed ID: 12801794
[No Abstract] [Full Text] [Related]
2. Discovery and development of biomarkers of neurological disease.
Dunckley T; Coon KD; Stephan DA
Drug Discov Today; 2005 Mar; 10(5):326-34. PubMed ID: 15749281
[TBL] [Abstract][Full Text] [Related]
3. Beyond the genome--SMi Conference 27-28 January 2003, London, UK.
Swinton J; Sheridan JM; Henning SW
IDrugs; 2003 Mar; 6(3):203-6. PubMed ID: 12838986
[TBL] [Abstract][Full Text] [Related]
4. When drugs development meets genomics.
Leung YF; Lam DS; Pang CP
Pharmacogenomics J; 2001; 1(4):237-8. PubMed ID: 11908765
[No Abstract] [Full Text] [Related]
5. Methods for the identification of vascular markers in health and disease: from the bench to the clinic.
Roesli C; Neri D
J Proteomics; 2010 Oct; 73(11):2219-29. PubMed ID: 20541635
[TBL] [Abstract][Full Text] [Related]
6. In biomarkers we trust?
Baker M
Nat Biotechnol; 2005 Mar; 23(3):297-304. PubMed ID: 15765081
[No Abstract] [Full Text] [Related]
7. Drug discovery and development using chemical genomics.
Sehgal A
Curr Opin Drug Discov Devel; 2002 Jul; 5(4):526-31. PubMed ID: 12197310
[TBL] [Abstract][Full Text] [Related]
8. Advances in molecular targets and cancer therapeutics.
Westwell AD
Drug Discov Today; 2004 Mar; 9(5):207-9. PubMed ID: 14980538
[No Abstract] [Full Text] [Related]
9. Will genomics revolutionise pharmaceutical R&D?
Noble D
Trends Biotechnol; 2003 Aug; 21(8):333-7. PubMed ID: 12902169
[TBL] [Abstract][Full Text] [Related]
10. Enabling parallel protein analysis through mass spectrometry.
Domon B; Alving K; He T; Ryan TE; Patterson SD
Curr Opin Mol Ther; 2002 Dec; 4(6):577-86. PubMed ID: 12596360
[TBL] [Abstract][Full Text] [Related]
11. Vita Genomics, Inc.
Shih-Hsin Wu L; Su CL; Chen E
Pharmacogenomics; 2007 Jun; 8(6):669-73. PubMed ID: 17559355
[TBL] [Abstract][Full Text] [Related]
12. New technologies for biomarker discovery in multiple sclerosis.
Comabella M; Racke MK
J Neuroimmunol; 2012 Jul; 248(1-2):1. PubMed ID: 22726889
[No Abstract] [Full Text] [Related]
13. Novel initiative seeks genetic causes of diabetes risk.
Ratner M
Nat Rev Drug Discov; 2004 Dec; 3(12):987. PubMed ID: 15645600
[No Abstract] [Full Text] [Related]
14. Streamlining drug discovery: finding the right drug against the right target to treat the right disease.
Ng JH; Ilag LL
Drug Discov Today; 2004 Jan; 9(2):59-60. PubMed ID: 15025066
[No Abstract] [Full Text] [Related]
15. Genomics and proteomics tools for compound mode-of-action studies in drug discovery.
Kley N; Ivanov I; Meier-Ewert S
Pharmacogenomics; 2004 Jun; 5(4):395-404. PubMed ID: 15165175
[TBL] [Abstract][Full Text] [Related]
16. In the pursuit of industrial proteomics.
Mitchell P
Nat Biotechnol; 2003 Mar; 21(3):233-7. PubMed ID: 12610565
[No Abstract] [Full Text] [Related]
17. Towards identification of true cancer biomarkers.
Diamandis EP
BMC Med; 2014 Sep; 12():156. PubMed ID: 25220599
[TBL] [Abstract][Full Text] [Related]
18. Proteomics approach to illustrate drug action mechanisms.
Wang Y; Chiu JF; He QY
Curr Drug Discov Technol; 2006 Sep; 3(3):199-209. PubMed ID: 17311565
[TBL] [Abstract][Full Text] [Related]
19. Iconix Biosciences, Inc.
Fielden MR; Halbert DN
Pharmacogenomics; 2007 Apr; 8(4):401-5. PubMed ID: 17391077
[TBL] [Abstract][Full Text] [Related]
20. siRNAs in drug discovery: target validation and beyond.
Natt F
Curr Opin Mol Ther; 2007 Jun; 9(3):242-7. PubMed ID: 17608022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
